About Design Therapeutics
Design Therapeutics is a company based in Carlsbad (United States) founded in 2006 by Aseem Ansari. Design Therapeutics has raised $170.5 million across 5 funding rounds from investors including BlackRock, Citadel and Janus Henderson Investors. The company has 54 employees. Design Therapeutics offers products and services including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program. Design Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Carlsbad, United States
- Employees 54
- Founders Aseem Ansari
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website designtx.com
- Social LinkedIn
- Legal Name Design Therapeutics, Inc.
- Net Profit-$69.79 M (USD)-40.74as on Dec 31, 2025
- EBITDA-$78.84 M (USD)-27.61as on Dec 31, 2025
- Total Equity Funding$170.5M (USD)
in 5 rounds
- Latest Funding Round$125M (USD), Series B
Jan 2021
- InvestorsBlackRock
& 9 more
- Employee Count54
Products & Services of Design Therapeutics
Design Therapeutics offers a comprehensive portfolio of products and services, including GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program.
Platform for developing small molecule therapies targeting genetic disorders.
Program advancing treatments for Friedreich ataxia genetic disease.
Program for therapies targeting Fuchs endothelial corneal dystrophy.
Program developing treatments for myotonic dystrophy disorder.
Program focused on therapies for Huntington’s disease patients.
Funding Insights of Design Therapeutics
Design Therapeutics has successfully raised a total of $170.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $170.5M
- Total Rounds 5
- Last Round Series B — $125M
- First Round $225,000
(Jan 2019)
- Investors Count 10
All 5 funding rounds of Design Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $125M | Series B | – | Logos | |
| Jun 2020 | $45.5M | Series A | – | SR One, Quan Capital | – |
| Jul 2019 | $225,000 | Grant | – | – | |
| Jun 2019 | $435,336 | Grant | – | – | |
| Jan 2019 | $225,000 | Grant | – | – |
10 investors in total: 10 institutional.
Investors in Design Therapeutics
Design Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Investments are directed toward early and growth stage companies. | – | quancapital.com | Pudong, China | |
Investments are focused across multiple sectors by the firm. | – | wrg.vc | Seattle, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Design Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Design Therapeutics
32 people are tracked at Design Therapeutics (16 in leadership, 9 in board & advisors, 7 in team); the tracked headcount is 54.
| Name | Role | Group |
|---|---|---|
Aseem Ansari | Co-Founder | Leadership |
Chaz Joseph | Associate Director, Accounting | Leadership |
Sean Jeffries | COO | Leadership |
Julie Burgess | Chief Accounting Officer | Leadership |
Jhuma Das, Ph.D. | Director, Computational Chemistry | Leadership |
Dawn Giangiulio | Senior Director, Accounting | Leadership |
Nancy Levin | Vice President | Leadership |
Mark Daniels | Vice President Clinical Operations | Leadership |
Aaron Young | Head of HR and People | Leadership |
Jim Kerr | Sr Vice President Of Product Development | Leadership |
Laura Weston | Vice President Of Product Development | Leadership |
Melanie Bell | Associate Director, Development Operations | Leadership |
Haiyan Tao | Director, Nonclinical Development | Leadership |
Hannah Han | Director, Formulation Development | Leadership |
Sam Moskowitz M.D. | Vice President | Leadership |
Marino Convertino | Sr. Director, Computational Chemistry | Leadership |
Simeon George | Director | Board & advisors |
Stella Xu | Director | Board & advisors |
Aseem Z. Ansari | Co-Founder & Scientific Advisor | Board & advisors |
Arsani William | Director | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for Design Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Design Therapeutics
Design Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DSGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Mar 2021
- Listed onNASDAQ: DSGN
- Listed entityDesign Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS25056L1035
- Share price$11.49 (-1.71% on the day) · 2026-10-08
- Market capitalisation$719.1M
- EPS (diluted, trailing year)$-1.18
- Volume (last session)674,849
Financials of Design Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$69.8M | -$78.8M |
| 2024 | – | -$49.6M | -$61.8M |
| 2023 | – | -$66.9M | -$77.7M |
| 2022 | – | -$63.3M | -$67.1M |
| 2021 | – | -$35.5M | -$35.7M |
Detailed financial statements for Design Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Design Therapeutics
4 dated milestones of Design Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Design Therapeutics is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Series B, of $125.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Design Therapeutics
Design Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| amicusrx.com | 2002 | Philadelphia, United States | $91M | 517 | Developer of therapies for rare and orphan diseases | |
| fulcrumtx.com | 2015 | Cambridge, United States | $114.67M | 104 | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. |
Detailed competitors of Design Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Design Therapeutics
The website of Design Therapeutics (designtx.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▼ 11.2% vs previous month
Latest news on Design Therapeutics
Complete news archive for Design Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Design Therapeutics
10 companies that operate in the same segment as Design Therapeutics (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Design Therapeutics
Design Therapeutics was founded in 2006 and raised its 1st funding round 13 years after it was founded.
Design Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Design Therapeutics is a funded company, having raised a total of $170.5M across 5 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Jan 2019.
Design Therapeutics has 54 employees.
Design Therapeutics was founded in 2006 and is based in Carlsbad, United States. Focus is placed on biotechnology within the pharmaceutical sector, where disease-modifying therapies for degenerative disorders are developed. Operations involve research and clinical development of targeted treatments. The companys domain, designtx.com, supports these activities. Co-founder Aseem Ansari contributes to strategic direction in this field.
Design Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Design Therapeutics offers GeneTAC Platform, Friedreich Ataxia Program, Fuchs Endothelial Corneal Dystrophy Program, Myotonic Dystrophy Program, and Huntington’s Disease Program.
Yes, Design Therapeutics is publicly traded on NASDAQ under the ticker symbol DSGN.
Design Therapeutics has 10 investors. Key investors include BlackRock, Citadel, Janus Henderson Investors, RA Capital, and Logos Capital.
Design Therapeutics operates through Design Therapeutics, Inc..